Rajagiri Round Table: Educating India- Listening to Innovative Teachers-76th Rajagiri Round Table  |  Cover Story: A New Era of Instructional Design  |  Best Practices: Continental Hospitals Set up a Super Specialty Clinic in IIT Hyderabad  |  Science Innovations: New cancer treatment developed by MIT  |  Leadership Instincts: Disappearance of Women researchers in Authorship during Pandemic  |  Technology Inceptions: MIT developed a New Successor for Mini Cheetah Robot  |  Science Innovations: IISc team develops novel computational model to predict ‘change blindness’  |  Science Innovations: Immune System Responds Better to Vaccination in Morning Hours  |  Teacher Insights: Training in Childhood Education, New Pedagogy Enabled Innovation in Teaching  |  International Policy: UNESCO Prize for Girls’ and Women’s Education 2021  |  Leadership Instincts: UNESCO Prize for Girls’ and Women’s Education 2021  |  Health Monitor: Intensive therapy better for Cerebral Palsy  |  Parent Interventions: Intensive therapy better for Cerebral Palsy  |  Science Innovations: Intensive therapy better for Cerebral Palsy  |  International Edu News: TutorComp- a new platform for online tutoring in UAE.  |  
May 19, 2021 Wednesday 12:23:29 AM IST

Pepper Compound Piperlongumine Effective Against Brain Cancer

Piperlongumine, a chemical compound found in Indian Long Pepper Plant (Piper longum) has been found to be effective against glioblastoma, one of the least treatable types of brain cancer, according to scientists at University of Pennsylvania (Perelman School of Medicine).

The pepper compound was found to hinder the activity of a protein called TRPV2, which is over expressed in glioblastoma in a way that appears to drive cancer progression. he scientists found that piperlongumine treatment radically shrank glioblastoma tumors and extended life in two animal models of this cancer, and also selectively destroyed glioblastoma cells taken from human patients.

This study gives us a much clearer picture of how piperlongumine works against glioblastoma, and in principle enables us to develop treatments that can be even more potent,” said study co-senior author Vera Moiseenkova-Bell, an associate professor of pharmacology and faculty director of the Electron Microscopy Resource Laboratory and Beckman Center for Cryo Electron Microscopy at Penn Medicine.

The researchers are now working to develop their approach in further preclinical studies, with the hope of one day testing it in clinical trials with glioblastoma patients. In addition, Moiseenkova-Bell’s structural findings will enable the researchers to experiment with piperlongumine and modified versions of it to develop an even stronger and more selective inhibitor of TRPV2.


Comments